Trimetazidine PCD Pharma Franchise Company
Cafoli Lifecare is a WHO-GMP certified PCD pharma franchise company offering a Trimetazidine range of 4 formulations across tablet and capsule forms to distributors and franchise partners across India, with district-level monopoly rights.
What is Trimetazidine?
Trimetazidine is an anti-anginal drug that works metabolically rather than haemodynamically. It partially inhibits the enzyme long-chain 3-ketoacyl-CoA thiolase, shifting cardiac muscle energy production away from fatty acid oxidation and towards glucose oxidation. Glucose oxidation yields more ATP per molecule of oxygen consumed, so the ischaemic myocardium copes better with a restricted oxygen supply — all without slowing the heart or lowering blood pressure. It is indicated as add-on therapy in chronic stable angina that is inadequately controlled by first-line anti-anginal drugs. It is prescription-only, and is contraindicated in Parkinson's disease and other movement disorders. Compound and pharmacology data are available on PubChem.
Trimetazidine Formulations Available with Cafoli Lifecare
The Trimetazidine portfolio comprises 4 formulations in tablet and capsule forms, including modified-release presentations suited to once- or twice-daily dosing. Details are shared on enquiry.
Therapeutic Applications of Trimetazidine
- Add-on therapy in chronic stable angina pectoris inadequately controlled by first-line agents
- Symptomatic management of ischaemic heart disease under cardiologist supervision
Prescribers are cardiologists and general physicians managing coronary artery disease. It is not a first-line anti-anginal and is not used for acute chest pain.
Why Trimetazidine is a High-Potential Molecule for Distributors
Trimetazidine occupies a gap that nothing else fills cleanly. Chronic stable angina patients in India are typically already loaded with haemodynamic drugs — beta-blockers, calcium channel blockers, nitrates — and a large fraction of them still get chest pain, yet cannot tolerate another drug that drops the pulse or the pressure any further. Trimetazidine is the one anti-anginal that adds symptom control without touching haemodynamics, so it goes on top of existing therapy rather than replacing it. Commercially that is a strong position: it is additive to the coronary artery disease market rather than competing for a slice of it, and India's CAD burden — early-onset, high-prevalence, still growing — supplies a large and expanding base of exactly the patients it suits. Therapy is chronic and daily, so scripts convert into steady monthly refills.
Why Choose Cafoli Lifecare for Your Trimetazidine Franchise
- Monopoly rights — one partner per district, territory protected
- WHO-GMP certified manufacturing and DCGI-approved formulations
- Promotional inputs — visual aids, doctor sample packs, literature, reminder gifts and MR bags
- 1000+ franchise partners across India
- On-time despatch, transparent net rates and dedicated order support
References
- PubChem — Trimetazidine compound record, National Library of Medicine
- PubMed — clinical literature on trimetazidine in stable angina
- WHO Model List of Essential Medicines
Our formulations of Trimetazidine find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: